查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1481290

急性淋巴母细胞白血病治疗市场 - 按治疗（化疗 [Hype-CVAD、Linker Regimen]、标靶治疗）、类型（B 细胞、T 细胞）、年龄组（儿童、成人）、性别（男性、女性）、治疗供应商全球预测，2024 - 2032 年

Acute Lymphoblastic Leukemia Therapeutics Market - By Therapy (Chemotherapy [Hype-CVAD, Linker Regimen], Targeted Therapy), Type (B-Cell, T-Cell), Age Group (Children, Adults), Gender (Male, Female), Treatment Providers, Global Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 203 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于人们越来越重视提高意识和早期诊断，急性淋巴母细胞白血病治疗市场规模预计在 2024 年至 2032 年期间以 6.8% 的复合年增长率扩大。加强对急性淋巴性白血病 (ALL) 症状和危险因子的认识活动和教育活动有助于患者及早发现。早期诊断能够及时开始治疗，从而改善患者的治疗结果和存活率。医疗保健提供者和倡导团体正在积极推动筛检计划，导致确诊病例增加。

此外，FDA 批准的新药，包括免疫疗法和基因疗法，为以前未满足的医疗需求的患者带来了新的希望。例如，2024 年1 月，开发下一代程序化T 细胞疗法的生物製药公司Autolus Therapeutics plc 宣布，美国FDA 批准了其用于治疗復发/难治性(r/r) 成人B 型患者的obecabtagene autoleucel 的急性淋巴母细胞白血病製剂许可申请。这些创新药物高度重视提高治疗效果和减少副作用，为所有患者和医疗保健提供者提供了一个有希望的途径，进一步推动了市场扩张。

ALL 治疗产业分为治疗、类型、年龄层、性别、治疗提供者和地区。

根据治疗情况，预计 2024 年至 2032 年标靶治疗领域的市场价值将产生 7% 的复合年增长率。该疗法透过精确靶向癌细胞，同时保护健康组织并减少副作用，提供个人化治疗方法。 Blinatumomab 和 Inotuzumab Ozogamicin 等单株抗体的突破在治疗 ALL 方面显示出显着的疗效。标靶治疗也抑制对癌细胞生存至关重要的特定分子途径，从而改善患者的预后，进一步促进其越来越多的采用。

在治疗提供者方面，癌症护理中心领域的急性淋巴性白血病治疗产业将从2024年到2032年实现7.1%的成长率。癌症护理中心也提供尖端治疗、临床试验和肿瘤专家，吸引了大量寻求最佳治疗结果的患者。此外，ALL 盛行率的上升以及对早期检测和治疗方案的认识不断提高将促进该细分市场的成长。

由于医疗保健支出的增加、医疗保健设施的改善以及对白血病的认识不断提高，亚太地区急性淋巴细胞白血病治疗行业预计在 2024 年至 2032 年间将增长 7.6%。此外，该地区庞大的人口基数提供了大量的患者资源。香港每年报告约 50 例新 ALL 病例，而全国则报告 15,000 例新病例。正在进行的研究计划预计将支持所有疗法的渗透。例如，2024年1月，香港中文大学医学院对儿童ALL进行了全州范围的多中心研究，证明CD9蛋白与ALL患者的预后密切相关。随着对个人化医疗和新颖治疗方法的日益重视，该区域产业必将呈现强劲成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 急性淋巴性白血病盛行率上升
      • 产品核准数量不断增加
    • 产业陷阱与挑战
      • 治疗费用高
      • 与治疗相关的不良反应
  • 成长潜力分析
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 公司市占率分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按疗法分类，2018 - 2032 年

  • 主要趋势
  • 化疗
    • Hyper-CVAD方案
    • CALGB 8811 方案
    • 接头方案
    • 核苷抑制剂
    • 昂卡斯帕
  • 标靶治疗
  • 放射治疗
  • 干细胞移植
  • 免疫疗法

第 6 章：市场估计与预测：按类型，2018 - 2032

  • 主要趋势
  • B细胞急性淋巴性白血病
  • T细胞急性淋巴性白血病
  • 费城染色体

第 7 章：市场估计与预测：按年龄划分，2018 年 - 2032 年

  • 主要趋势
  • 孩子们
  • 成年人

第 8 章：市场估计与预测：按性别划分，2018 年 - 2032 年

  • 主要趋势
  • 男性
  • 女性

第 9 章：市场估计与预测：按治疗提供者划分，2018 年 - 2032 年

  • 医院和诊所
  • 癌症护理中心
  • 研究和学术机构

第 10 章：市场估计与预测：按地区划分，2018 年 - 2032 年

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 中东和非洲其他地区

第 11 章：公司简介

  • Bristol Myer Squibb Company
  • Celegene Corporation
  • Eisai Co Ltd.
  • Erytech Pharma
  • F. Hoffmann-La Roche Ltd.
  • Genmab A/S
  • GlaxoSmithKline PLC
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
简介目录
Product Code: 8368

Acute Lymphoblastic Leukemia Therapeutics Market size is poised to expand at 6.8% CAGR during 2024-2032 due to the increasing emphasis on growing awareness and early diagnosis. Greater awareness campaigns and educational initiatives about acute lymphoblastic leukemia (ALL) symptoms and risk factors have led to earlier detection among patients. Early diagnosis enables prompt initiation of treatment for improving patient outcomes and survival rates. Healthcare providers and advocacy groups are actively promoting screening programs, leading to a higher number of diagnosed cases.

Furthermore, FDA approvals for new drugs, including immunotherapies and gene therapies are providing patients with previously unmet medical needs with new hope. For instance, in January 2024, Autolus Therapeutics plc, a biopharmaceutical firm developing next-gen programmed T-cell therapies, announced that the U.S. FDA approved its Biologics License Application for obecabtagene autoleucel in patients with relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia. With strong focus on enhancing treatment efficacy and reducing side effects, these innovative medicines offer promising avenues for ALL patients and healthcare providers, further propelling the market expansion.

The ALL therapeutics industry is segmented into therapy, type, age group, gender, treatment provider, and region.

Based on therapy, the market value from the targeted therapy segment is anticipated to generate 7% CAGR during 2024-2032. This therapy offers personalized treatment approaches by precisely targeting cancer cells while sparing healthy tissues and reducing side effects. Breakthroughs in monoclonal antibodies, such as Blinatumomab and Inotuzumab Ozogamicin, have shown remarkable efficacy in treating ALL. Targeted therapies also inhibit specific molecular pathways crucial for cancer cell survival for improving patient outcomes, further contributing to their increasing adoption.

In terms of treatment provider, the acute lymphoblastic leukemia therapeutics industry from the cancer care centers segment will witness 7.1% growth rate from 2024 to 2032. These specialized centers provide comprehensive care, including diagnosis, treatment, as well as ongoing support for leukemia patients. Cancer care centers also offer access to cutting-edge treatments, clinical trials, and expert oncologists, attracting a significant patient pool seeking optimal outcomes. Additionally, the rising prevalence of ALL and the increasing awareness of early detection and treatment options will boost the segment growth.

Asia Pacific acute lymphoblastic leukemia therapeutics industry is anticipated to depict a 7.6% growth rate between 2024 and 2032 due to the increasing healthcare expenditure, improving access to healthcare facilities, and rising awareness about leukemia. Additionally, the large population base in the region is providing a significant patient pool. Each year, around 50 new cases of ALL are reported in Hong Kong, with 15,000 new cases reported nationwide. The ongoing research initiatives are expected to support the penetration of ALL therapeutics. For instance, in January 2024, the Chinese University of Hong Kong Faculty of Medicine performed a statewide, multicenter research on childhood ALL and proved that the CD9 protein is strongly related to the prognosis of ALL patients. With the growing emphasis on personalized medicine and novel treatment approaches, the regional industry is set to exhibit robust growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definition
  • 1.2 Base estimates & calculations
  • 1.3 Forecast parameters
  • 1.4 Data collection
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of acute lymphoblastic leukemia
      • 3.2.1.2 Increasing number of product approvals
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High treatment cost
      • 3.2.2.2 Adverse effects associated with the treatment
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
    • 3.5.1 Supplier power
    • 3.5.2 Buyer power
    • 3.5.3 Threat of new entrants
    • 3.5.4 Threat of substitutes
    • 3.5.5 Industry rivalry
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Therapy, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Chemotherapy
    • 5.2.1 Hyper - CVAD regimen
    • 5.2.2 CALGB 8811 regimen
    • 5.2.3 Linker regimen
    • 5.2.4 Nucleoside inhibitors
    • 5.2.5 Oncaspar
  • 5.3 Targeted therapy
  • 5.4 Radiation therapy
  • 5.5 Stem cell transplantation
  • 5.6 Immunotherapy

Chapter 6 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 B-cell acute lymphoblastic leukemia
  • 6.3 T-cell acute lymphoblastic leukemia
  • 6.4 Philadelphia chromosome

Chapter 7 Market Estimates and Forecast, By Age Group, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Children
  • 7.3 Adults

Chapter 8 Market Estimates and Forecast, By Gender, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Male
  • 8.3 Female

Chapter 9 Market Estimates and Forecast, By Treatment Providers, 2018 - 2032 ($ Mn)

  • 9.1 Hospitals & clinics
  • 9.2 Cancer care centers
  • 9.3 Research and academic institutes

Chapter 10 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 Bristol Myer Squibb Company
  • 11.2 Celegene Corporation
  • 11.3 Eisai Co Ltd.
  • 11.4 Erytech Pharma
  • 11.5 F. Hoffmann-La Roche Ltd.
  • 11.6 Genmab A/S
  • 11.7 GlaxoSmithKline PLC
  • 11.8 Novartis AG
  • 11.9 Pfizer, Inc.
  • 11.10 Sanofi S.A.